AOD-9604: Research Overview, Purity and Half-Life

Few research compounds carry a preclinical record and a clinical record that disagree as sharply as AOD-9604 does. Rodent work published in 2001 reported that chronic treatment with the lipolytic C-terminal fragment of human growth hormone altered lipid metabolism in obese mice and in beta-3 adrenergic receptor knockout mice (Endocrinology, PMID 11713213), while a companion paper described increased fat oxidation and weight loss in obese mice given either human growth hormone or a modified C-terminal fragment (Int J Obes Relat Metab Disord, PMID 11673763). The human obesity program built on that signal never produced an approved medicine.

Our team supplies AOD-9604 to laboratories, and the question researchers ask us most often isn't what the fragment did in a mouse. It's whether the vial on the bench actually contains AOD-9604 at the purity printed on the label. Those are two separate problems, and reading the literature only solves one of them.

What is AOD-9604?

AOD-9604 is a synthetic analogue of the C-terminal 176 to 191 region of human growth hormone, modified with an added N-terminal tyrosine. Originally developed as an anti-obesity candidate, it's now studied mainly in lipid-metabolism and cartilage models. AOD-9604 holds no drug approval in any major market and is supplied strictly for laboratory research.

The most common over-simplification is that AOD-9604 is 'growth hormone without the growth hormone problems'. That line flattens a real pharmacological distinction into a slogan. The fragment was isolated because investigators wanted the lipolytic portion of the hormone separated from the growth-promoting, IGF-1-mediated actions of the intact 191-amino-acid molecule. What follows covers the proposed mechanism, what the animal and human studies actually found, what the literature reports on adverse effects and clearance, how laboratories verify identity and purity, and how AOD-9604 compares with related research compounds.

What is AOD-9604 in molecular terms?

AOD-9604 is a short synthetic peptide corresponding to the lipolytic domain at the tail end of human growth hormone, with a tyrosine residue added at the N-terminus. In papers, catalogues and certificates you'll see the same molecule written several ways: AOD9604 without the hyphen, hGH fragment 176-191, and Tyr-hGH(177-191). They are not different compounds.

The molecule came out of a development program at Metabolic Pharmaceuticals, and the clearest single snapshot of that program is the 2004 compound profile published in Current Opinion in Investigational Drugs (PMID 15134286). The design logic was simple. Intact growth hormone drives both lipolysis and IGF-1 mediated growth signalling, so isolating the lipolytic region ought to decouple one from the other.

Because the sequence is short and openly published, AOD-9604 is easy to synthesise and equally easy to mis-synthesise. Deletion sequences, incomplete deprotection and residual trifluoroacetate left over from purification are the routine failure modes, and not one of them is visible in a white lyophilised cake. Our introductory overview of AOD-9604 walks through the naming conventions, and our page on reported research benefits maps which endpoints the published work actually examined.

How is the fragment thought to work?

The proposed mechanism is stimulation of lipolysis, the enzymatic breakdown of stored triglyceride in adipocytes, alongside reduced lipogenesis, the synthesis of new fat. A 2000 paper in Hormone Research examined the metabolic actions of this synthetic lipolytic domain directly (PMID 11146367), and the recurring claim across this body of work is that the metabolic effect appears without the IGF-1 elevation characteristic of intact growth hormone.

Here's the detail most summaries get backwards. The 2001 Endocrinology study didn't simply show that the fragment works through beta-3 adrenergic receptors. It compared obese mice against beta-3 adrenergic receptor knockout mice specifically to test whether that receptor is required, and the reported outcome complicates the tidy 'it activates beta-3 receptors' explanation that circulates in secondary sources. Research suggests the lipolytic response isn't strictly dependent on intact beta-3 signalling, which matters enormously if you're designing a knockout or antagonist experiment around it.

Our team has watched research groups cite the paper title rather than the finding more than once. Our deeper write-up on beta-3 adrenergic activation and AOD-9604 separates what the knockout model showed from what gets attributed to it.

What does the animal research report?

The animal literature on this fragment splits into two distinct streams: metabolic and musculoskeletal. On the metabolic side, the 2001 obese-mouse studies remain the foundation, reporting increased fat oxidation and reduced body weight with chronic treatment (PMID 11673763).

The musculoskeletal stream is newer and, for many labs, more interesting. A 2015 study in Annals of Clinical and Laboratory Science evaluated the compound alone and in combination with hyaluronic acid in a rabbit osteoarthritis model (PMID 26275694), which is the origin of most current cartilage-related interest. A 2026 review in JAAOS Global Research and Reviews places therapeutic peptides in orthopaedics into context, including their applications, challenges and limitations (PMID 41490200).

There's also an outlier worth knowing about. A 2022 paper in Drug Design, Development and Therapy reported that human growth hormone fragment 176-191 enhanced the toxicity of doxorubicin-loaded chitosan nanoparticles against MCF-7 breast cancer cells (PMID 35783198), an in vitro drug-delivery application entirely unrelated to metabolism. Our comparison of animal versus human findings for AOD-9604 sets these results side by side, and we cover the joint-tissue literature in more detail in our pages on cartilage regeneration research, cartilage repair study design and bone repair mechanisms.

What happened in human clinical development?

The compound reached mid-stage human trials for obesity and then stopped. The gap between the preclinical signal and the clinical result is the single most important fact about AOD-9604, and it's the fact most often left out of summaries. The 2004 Current Opinion in Investigational Drugs profile captures the program at the point of maximum optimism; no approval followed in any jurisdiction.

That trajectory is not unusual for the category. A 2026 review in Frontiers in Endocrinology examines performance-enhancing peptides that modulate the GH-IGF1 axis and explicitly frames the distance between clinical evidence and real-world self-administration (PMID 42395176). A 2026 Sports Medicine review covers the safety and efficacy evidence base for approved and unapproved peptide therapies in musculoskeletal injury and athletic performance (PMID 41966639), and the conclusion researchers should take from it is that unapproved status usually reflects an evidence gap rather than a conspiracy.

We track the current trial landscape on our clinical trials page for AOD-9604, and our comparison with GLP-1 class agents explains why the two sit in completely different evidence tiers.

What do studies report about side effects, and what is still unknown?

The published human experience with AOD-9604 is limited to early and mid-phase trial reporting, which described the compound as generally well tolerated and, notably, reported no meaningful change in IGF-1 or glucose handling. That is a narrow evidence base. Tolerability in a short, monitored trial is not the same as a characterised long-term safety profile, and no such profile exists in the indexed literature.

The real unknowns are structural. There's no large-scale human safety dataset, no long-duration exposure data, and no systematic pharmacovigilance for a compound distributed outside approved channels. The 2026 Sports Medicine review is blunt about exactly this category of gap across unapproved peptides. Impurity-driven effects are a separate and under-discussed risk: a research-grade preparation carrying deletion sequences or elevated residual solvent can produce confounded results that look like compound effects.

Our pages on what the side-effect studies report and on documented contraindications in the literature go further, and we address the recurring interaction questions researchers encounter in our notes on alcohol and caffeine.

What is known about half-life and clearance?

There's no well-characterised, widely published human half-life figure for AOD-9604, and anyone quoting a precise number should be asked for the citation. Short unmodified peptides of this class are generally subject to rapid enzymatic degradation by circulating and tissue peptidases, which is the pharmacokinetic reality that shaped how anti-doping scientists approached the molecule.

The most useful published work here is a 2015 paper in Drug Testing and Analysis covering detection and in vitro metabolism of the compound (PMID 25208511). Metabolite identification work of that type exists precisely because the parent molecule doesn't persist long enough to make parent-compound detection reliable on its own.

Then there's the finding that explains why this fragment needed its own analytical method at all. A 2013 Drug Testing and Analysis study reported that AOD-9604 does not influence the WADA human growth hormone isoform immunoassay (PMID 24124033). The standard growth hormone screen compares ratios of pituitary GH isoforms, and a 16-residue fragment simply isn't visible to it, so dedicated liquid chromatography tandem mass spectrometry methods were developed instead. The broader methodology is reviewed in Mass Spectrometry Reviews (PMID 26213263). Our page on reported timelines in body-composition models covers what study durations the literature has used.

How does it compare with related research compounds?

Researchers evaluating this fragment are usually weighing it against other metabolic or GH-axis research compounds. The table below compares molecule type, primary target and the strength of the published evidence, because evidence tier is the variable most often ignored during procurement.

Our head-to-head analysis of 5-Amino-1MQ versus AOD-9604 breaks the mechanism difference down further, and our survey of research alternatives in 2026 covers the wider field.

How do laboratories verify a vial before using it?

Three documents answer the identity and purity question, and a vial without all three is an unknown quantity. First, reverse-phase HPLC purity, which separates the target peptide from deletion sequences and process impurities; research-grade material is typically reported at 98 percent or higher. Second, mass spectrometry identity confirmation, usually ESI-MS or MALDI-TOF, where the observed mass must match the theoretical mass calculated from the published sequence. Third, a batch number on the certificate that matches the batch number on the vial.

A certificate without a matching batch number is a marketing document, not a certificate. We've seen generic certificates recycled across unrelated lots often enough that batch matching is now the first thing our team checks when researchers send over a competitor document for a second opinion.

Also cross-check the molecular formula and CAS registry entry printed on the certificate against the sequence described in the primary literature, since transcription errors on supplier paperwork are more common than outright fraud. Real Peptides supplies AOD-9604 for laboratory research with a published certificate of analysis. For the arithmetic side of experimental planning, our concentration reference for AOD-9604 covers milligram-per-millilitre calculation and how to read vial content off a certificate.

How should the lyophilised powder be stored in a laboratory?

Lyophilised AOD-9604 is stored frozen, conventionally at minus 20 degrees Celsius or colder, protected from light and moisture. The powder is hygroscopic, which is why vials should be brought to room temperature before opening; condensation forming on cold peptide introduces water that accelerates hydrolysis and oxidation of the sequence.

Short ambient excursions during shipping are normal for lyophilised peptide and are generally tolerated far better than excursions in the solubilised state. Once in solution, stability drops sharply, refrigerated conditions of 2 to 8 degrees Celsius apply, and repeated freeze-thaw cycling is the fastest route to degraded material. Aliquoting to avoid repeated cycling is standard laboratory practice.

The practical consequence worth internalising: a degraded preparation of AOD-9604 doesn't announce itself. It looks identical, dissolves identically, and simply produces a weaker or absent signal that gets misread as a negative result.

Is it legal, and what does research use only mean?

AOD-9604 is not an approved drug in the United States, the European Union or any other major market, and it has not been authorised for human or veterinary use. Regulators have declined to approve it and have flagged growth hormone fragments among substances raising safety concerns in the pharmacy compounding context. All compounds discussed on this page are sold for research use only and are not for human consumption.

It also sits on the World Anti-Doping Agency prohibited list under the peptide hormones and growth factors class, which explicitly captures growth hormone fragments. That status, combined with the 2013 immunoassay finding, is why targeted mass spectrometry methods for the compound exist in doping-control laboratories. Legal possession for legitimate laboratory research and legitimate use in sport are entirely separate questions, and conflating them is how researchers get into trouble.

How we researched this page

Everything above is drawn from peer-reviewed literature indexed on PubMed, searched across the compound's synonyms including AOD9604 and hGH fragment 176-191, and every study claim on this page carries a direct PubMed link so you can read the source rather than trust our summary. We have not conducted first-party laboratory testing of the compound and make no original experimental claims here.

Where the literature is thin, we've said so instead of filling the gap with a number. Half-life is the clearest example: a precise figure would be more citable and less honest. We update this page as new indexed literature appears, including the 2026 reviews cited above.

What If: Laboratory Scenarios

What if the certificate lists HPLC purity but no mass spectrometry data?

Treat the material as unidentified until mass confirmation is supplied. HPLC purity tells you the preparation contains one dominant species; it doesn't tell you that species is the correct 176-191 sequence. A deletion analogue missing a single residue can elute cleanly and report high purity while carrying a mass several daltons off target. Request the MS trace or the observed-versus-theoretical mass figure before the material enters an experiment.

What if a shipment of AOD-9604 arrives at ambient temperature?

Document the arrival condition, then assess the physical state of the cake before anything else. Lyophilised peptide is substantially more tolerant of transient warmth than solubilised peptide, and brief ambient transit is routine in peptide logistics. A cake that has collapsed, discoloured or gone visibly tacky indicates moisture ingress, which is a different and more serious problem than temperature alone.

What if a cell model shows no lipolytic signal at all?

Rule out the material before revising the hypothesis. Degraded AOD-9604, a deletion-sequence impurity or a mismatch between the stated and actual vial content will all produce a flat result indistinguishable from a true negative. The published mechanism also isn't uniform across models, and the beta-3 knockout work is a reminder that receptor assumptions carried over from secondary sources frequently don't survive contact with a primary paper.

The blunt truth about a peptide with a 25-year paper trail

Here's the honest answer: the mouse data for AOD-9604 was strong, the human data was not, and the obesity story effectively ended in mid-stage trials well over a decade ago. Anyone presenting this fragment as a validated fat-loss agent is describing rodent literature and hoping you won't check. What the compound still has is a specific, legitimate research case in joint-tissue and lipid-metabolism models, plus an unusually well-documented analytical chemistry footprint. That's a real reason to study it. It is not the same reason it was originally marketed.

For researchers extending this work, our related analyses cover the mechanistic differences between 5-Amino-1MQ and AOD-9604, how the two compare on evidence strength, the combined-compound literature in fat-metabolism models, observations reported before and after study periods, how those reported observations hold up on closer reading, the biomarkers studies track, body-composition research design, reported timelines in cartilage repair models and the literature on combining AOD-9604 with other peptides.

AOD-9604 is a useful case study in how a compound survives the failure of its own headline indication. The metabolic program collapsed, and yet twenty-five years of sequence characterisation, metabolite mapping and detection chemistry left behind a molecule that's easier to verify than almost anything else in the research peptide category. That verification trail is the asset. If you're going to work with this fragment, work with the paper trail too, because the chemistry on the certificate is the only part of the story that has never contradicted itself.